Outset Medical, Inc. (NASDAQ:OM) Short Interest Down 13.6% in February

Outset Medical, Inc. (NASDAQ:OM) saw a significant decline in short interest in February. As of February 27th, there was short interest totaling 1,915,455 shares, a decline of 13.6% from the February 12th total of 2,217,364 shares. Currently, 10.7% of the company’s stock are sold short. Based on an average daily trading volume, of 247,824 shares, the short-interest ratio is presently 7.7 days. Based on an average daily trading volume, of 247,824 shares, the short-interest ratio is presently 7.7 days. Currently, 10.7% of the company’s stock are sold short.

Insiders Place Their Bets

In other news, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the transaction, the general counsel directly owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. The trade was a 20.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Marc Nash sold 5,375 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $27,520.00. Following the sale, the executive vice president owned 42,785 shares of the company’s stock, valued at $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 40,910 shares of company stock worth $193,040 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Outset Medical

A number of institutional investors and hedge funds have recently modified their holdings of OM. Geode Capital Management LLC raised its stake in shares of Outset Medical by 955.9% during the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after buying an additional 376,196 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Outset Medical during the second quarter valued at approximately $78,000. Ensign Peak Advisors Inc lifted its holdings in Outset Medical by 272.4% in the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock valued at $6,042,000 after acquiring an additional 230,065 shares during the period. JPMorgan Chase & Co. boosted its position in Outset Medical by 662.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after purchasing an additional 7,344 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in Outset Medical in the 2nd quarter worth approximately $34,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on OM shares. Stifel Nicolaus reduced their target price on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a research report on Wednesday, December 17th. BTIG Research decreased their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Outset Medical Stock Performance

OM stock traded up $0.28 during midday trading on Tuesday, reaching $3.63. The stock had a trading volume of 113,227 shares, compared to its average volume of 866,592. The stock has a market cap of $66.47 million, a PE ratio of -0.53 and a beta of 2.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.40 and a current ratio of 6.67. The firm has a fifty day simple moving average of $4.25 and a two-hundred day simple moving average of $7.78. Outset Medical has a 52-week low of $3.00 and a 52-week high of $21.98.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.